Atossa Therapeutics Inc (ATOS)

[boston127]

History of dilution and RS keeps this down.

Being granted FDA expanded access in December should have been considered a massive achievement for this microcap stock. The update in February disclosing no safety or tolerability issues and a reduction of the cancer cell biological activity also should have been considered a significant positive step. Neither was likely because of ATOS' history as a dilute and reverse split value destroyer for shareholders and skepticism over its science.

The FDA approving oral Endoxifen for post-operative use is a signal to the market that this is something that truly worked for this individual. It would have been cruel to not let her continue with treatment. The disclosure that "the cancer cell biological activity was reduced by two measures: the Ki-67 activity decreased by 50 percent, and the estrogen receptor content decreased by over 20 percent" certainly helped to show the scale of improvement and robustness of the science. Years of R&D spending has finally led to hopes of a "miracle", and therefore very marketable and lucrative, drug.